Q

49. Lempiäinen P, Mykkänen L, Pyörälä K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100:123-128.

50. Despres J-P. The insulin resistance-dyslipidemia syndrome: The most prevalent cause of coronary artery disease? Can Med Assoc J 1993; 148:1339-1340.

51. Lamarche B, Tchernof A, Maurieige P, Cantin B, Degenais GR, Lupien PJ, Despres J-P. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279:1955-1961.

52. Kannel WB. Lipids, diabetes, and coronary heart disease: Insights from the Framing-ham Study. Am Heart J 1985; 110:1100-1107.

53. Kannel WB, D'Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and the risk of cardiovascular disease: The Framingham experience. Am Heart J 1999; 120:672-676.

54. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792-1801.

55. Danesh J. Smoldering arteries? Low-grade inflammation and coronary heart disease. JAMA 1999; 282:2169-2170.

56. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA 1998; 279:1477-1482.

57. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22(suppl 3):C10-C13.

58. Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. PNAS(USA) 2000; 92:11371-11376.

59. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: a transgenic mouse. Genes Devel 1998; 12:3168-3181.

60. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43:527-550.

61. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor Y and metabolic disease. Annu Rev Biochem 2001; 70:341-367.

62. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103:253-259.

63. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor a: A key component of the obesity-diabetes link. Diabetes 1994; 43:1271-1278.

64. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999; 103:931943.

65. Dib K, Whitehead JP, Humphreys PJ, Soos MA, Baynes KCR, Kumar S, Harvey T, O'Rahilly S. Impaired activation of phosphoinositide 3-kinase by insulin in fi-broblasts from patients with severe insulin resistance and pseudoacromegaly: A disorder characterized by selective postreceptor insulin resistance. J Clin Invest 1998; 101:1111-1120.

0 0

Post a comment